TheEdgeResearch
Home / Stocks / KNSA

Kiniksa Pharmaceuticals International, plc (KNSA)

NASDAQ Healthcare Medical - Pharmaceuticals
$79.26 ▼ -2.05%
Market Cap
$6.04B
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Beta
0.07
52-Wk Range
29.9-82.94
CEO
Sanj K. Patel
Country
GB
Currency
USD

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2…

Open full interactive analysis & DCF →